Business
Eli Lilly and : Foundayo (orforglipron), a once-daily pill taken without food or water restrictions, was associated with reduced body weight by up to 13% in adults 65 and older with obesity or overweight, in new analysis of ATTAIN-1/2
Eli Lilly and : Foundayo (orforglipron), a once-daily pill taken without food or water restrictions, was associated with reduced body weight by up to 13% in
About this update from Eli Lilly And Company
[{"type":"text","content":"Once-daily oral Foundayo was associated with statistically significant body weight reductions vs. placebo in adults ≥65 years at all three doses studied at 72 weeks (p<0.001 for all)\n In adults ≥65 without type 2 diabetes (ATTAIN-1), Foundayo at the highest approved dose (17.2 mg) was associated with 13% mean body weight reduction vs. 1.6% with placebo at 72 weeks (p<0.001)\n Results were consistent across both age groups (<65 and ≥65 years), with and without type 2 diabetes, supporting Foundayo as a treatment option across a broad adult population\n Starting July 1, 2026, Medicare beneficiaries can access Foundayo through Medicare GLP-1 Bridge at a $50 monthly copay\n INDIANAPOLIS, May 22, 2026 - Eli Lilly and Company (NYSE: LLY) announced a new analysis from the Phase 3 ATTAIN-1 and ATTAIN-2 trials showing that Foundayo (orforglipron), was associated with clinically significant body weight reductions in adults aged 65 and older with obesity or overweight, with or without type 2 diabetes. Foundayo is the only approved GLP-1 pill that can be taken any time of day without food or water restrictions. The post-hoc analysis was recently presented at ECO 2026 in Istanbul, Turkey.1\n Key results: Weight loss in adults 65 and older\n Foundayo at all doses tested was associated with statistically significant reductions in body weight compared with placebo at 72 weeks in adults ≥65, in both trials using the efficacy estimand (all p<0.001).2\n \n \n ATTAIN-1 (participants with obesity or overweight and without T2D): At the highest dose, mean body weight reduction reached 13% in the observed data for adults 65 and older. Participants ≥65 years were associated with mean body weight reductions of -7.9% (5.5 mg), -11.3% (9 mg), and -13.0% (17.2 mg) vs. -1.6% with placebo. Comparable mean body weight reductions of -7.7% (5.5 mg), -9.2% (9 mg), and -12.4% (17.2 mg) were observed in adults <65 vs. -0.8% placebo.\n \n \n ATTAIN-2 (participants with obesity or overweight and T2D): Participants ≥65 years were associated with mean body weight reductions of -7.5% (5.5 mg), -8.3% (9 mg), and -12.2% (17.2 mg) vs. -2.3% placebo. Comparable mean body weight reductions of -5.0% (5.5 mg), -7.6% (9 mg), and -9.9% (17.2 mg) were observed in adults <65 vs. -2.2% placebo.\n Expert perspective: What the results could mean for patients\n \"Wei...